mRNA-based cancer immunotherapies: an evolving regulatory landscape
• BioNTech´s oncology pipeline: combining different modalities to address the continuum of cancer treatment
• The regulatory classification of mRNA-based medicinal products
• The specific challenges of fully individualized mRNA-based therapies